With IACS-010759, KRAS-negative pancreatic cancer cells were selectively targeted since their glycolysis remained low, while KRAS-positive cells adapted by upregulating glycolysis as a compensatory mechanism [14]. Here, KRAS is linked to pancreatic neoplasm.